Summary:
Study to evaluate the safety and effictiveness of elagolix versus placebo to reduce uterine bleeding associated with uterine fibroids and to reduce fibroid volume.
Qualified Participants Must:
• Be between 20 and 49 years of age
•
Be pre-menopausal
•
Have heavy or long periods
•
Have uterine fibroids
Qualified Participants May Receive:
Investigational medication, investigation related physical exam, mammograms (if needed), DEXA scan, EKG, pelvic ultrasounds, other study related testing and financial reimbursement for time and travel.